An investigator-initiated Phase II clinical trial of recombinant human HGF started at the Tohoku and Osaka University Hospitals for the treatment of amyotrophic lateral sclerosis (ALS).

An investigator-initiated Phase II clinical trial of recombinant human HGF started at the Tohoku and Osaka University Hospitals for the treatment of amyotrophic lateral sclerosis (ALS).